Johnson & Johnson (NYSE:JNJ) Shares Sold by Linscomb & Williams Inc.

Posted by Defense World Staff on Aug 30th, 2023

Linscomb & Williams Inc. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 15.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,823 shares of the company’s stock after selling 14,158 shares during the quarter. Linscomb & Williams Inc.’s holdings in Johnson & Johnson were worth $11,753,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Three Bridge Wealth Advisors LLC lifted its holdings in Johnson & Johnson by 52.2% in the first quarter. Three Bridge Wealth Advisors LLC now owns 7,064 shares of the company’s stock worth $1,095,000 after purchasing an additional 2,423 shares during the period. Mount Yale Investment Advisors LLC raised its position in Johnson & Johnson by 3.7% in the first quarter. Mount Yale Investment Advisors LLC now owns 28,105 shares of the company’s stock worth $4,356,000 after acquiring an additional 1,000 shares in the last quarter. Commonwealth Equity Services LLC raised its position in Johnson & Johnson by 1.8% in the first quarter. Commonwealth Equity Services LLC now owns 1,801,013 shares of the company’s stock worth $279,157,000 after acquiring an additional 31,827 shares in the last quarter. Marco Investment Management LLC raised its holdings in Johnson & Johnson by 0.5% during the 1st quarter. Marco Investment Management LLC now owns 33,467 shares of the company’s stock worth $5,187,000 after buying an additional 166 shares during the period. Finally, Burgundy Asset Management Ltd. raised its holdings in Johnson & Johnson by 44.3% during the 1st quarter. Burgundy Asset Management Ltd. now owns 1,246,550 shares of the company’s stock worth $193,215,000 after buying an additional 382,744 shares during the period. 68.40% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $164.31 on Wednesday. The stock’s fifty day moving average is $166.68 and its 200-day moving average is $161.50. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The stock has a market capitalization of $427.04 billion, a PE ratio of 33.26, a PEG ratio of 2.76 and a beta of 0.54. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.62 by $0.18. The business had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the business earned $2.59 earnings per share. Equities research analysts expect that Johnson & Johnson will post 10.75 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be issued a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 2.90%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is 96.36%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The disclosure for this sale can be found here. Insiders have sold a total of 47,163 shares of company stock worth $7,928,856 over the last 90 days. Insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on JNJ. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. Barclays increased their price objective on Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a research report on Monday, July 24th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, August 22nd. JPMorgan Chase & Co. upped their target price on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Finally, StockNews.com started coverage on Johnson & Johnson in a research note on Thursday, August 17th. They issued a “strong-buy” rating for the company. Eight investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $171.80.

Read Our Latest Analysis on JNJ

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.